MOESM4 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Nägele
Andrea Kratzer
Gerhard Zugmaier
Chris Holland
Youssef Hijazi
Max Topp
Nicola Gökbuget
Patrick Baeuerle
Peter Kufer
Andreas Wolf
Matthias Klinger
10.6084/m9.figshare.c.3783488_D4.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM4_of_Changes_in_clinical_laboratory_parameters_and_pharmacodynamic_markers_in_response_to_blinatumomab_treatment_of_patients_with_relapsed_refractory_ALL/5024294
Additional file 4. Available patient numbers (N) for analysis of distribution profiles of CD8+ and CD4+ T cells and subsets in Fig. 4.
2017-05-18 05:00:00
Acute lymphoblastic leukemia
Blinatumomab
Bispecific
BiTE®
CD19
Liver enzymes
Pharmacodynamics